Hypertension
Lentiviral vectors bear clones that offer long-term ACE2 secretion
Published in Gene Therapy Weekly, December 23rd, 2004
According to a study from the United States, "angiotensin-converting enzyme 2 (ACE2) is a newly discovered, membrane-bound aminopeptidase responsible for the production of vasodilatory peptides such as angiotensin 1-7 (Ang 1-7). Thus, ACE2 is important in counteracting the adverse, vasoconstrictor effects of angiotensin II (Ang II). The objective of the present study was to clone and characterize a constitutively secreted form of ACE2 as a prelude to an investigation into its therapeutic potential in hypertension."
"A truncated form of ACE2 was cloned into a lentiviral vector behind...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-12-23)
More Articles from Gene Therapy Weekly
- Brain Cancer
Co-expressed genes in virus-driven therapy block glioma invasion - Diabetes Prevention
Gene-modified stem cells prevent type 1 diabetes in murine models - Fetal Development
Non-viral gene transfer tracks gene expression in murine embryos - Gene Promoters
G-quadruplex ligands may stop c-myc activity in tumor cells - Oncology
Sodium channel subunit beta gene delivery complements anticancer therapy - Amyotrophic Lateral Sclerosis
Promising results seen in the battle against incurable muscle disease - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
